Miglustat
Top View
- 205494Orig1s000
- Cell Models of Lipid-Rich Α-Synuclein Aggregation Validate Known Modifiers of Α-Synuclein Biology and Identify Stearoyl-Coa Desaturase
- FDA Orphan Drug Designations for Lysosomal Storage Disorders – A
- The Empire Plan Prescription Drug Program Specialty Pharmacy Program Drug List for Advanced Flexible Formulary
- For Peer Review Only - Page 1 of 59 BMJ Open
- Essential List of Medicinal Products for Rare Diseases: Recommendations from the Irdirc Rare Disease Treatment Access Working Group William A
- Supplement 3 List of Treatable Iems
- Self-Administered Specialty Drug List
- Eliglustat (Cerdelga®) EOCCO POLICY Policy Type: PA/SP Pharmacy Coverage Policy: EOCCO135
- 5.01.576 Drugs for Rare Diseases
- TITLE: Eliglustat Tartrate, Miglustat, Imiglucerase, Velaglucerase Or A
- Evaluation of Carcinogenicity Studies of Medicinal Products for Human Use Authorised Via the European Centralised Procedure
- Presentation
- Specialty Pharmacy Program Drug List
- 5 Treatment: Present Status and New Trends
- MIGLUSTAT DIPHARMA IS NOW AVAILABLE in SWITZERLAND Chiasso, Switzerland, February 16Th 2021 – – Swiss-Based Dipharma S.A
- State and Specialty Pharmacy Drug Reimbursement Rates
- ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019